WORCESTER, Mass., Nov. 12 /PRNewswire-FirstCall/ -- Advanced Cell Technology's (OTCBB: ACTC) Chief Scientific Officer, Robert Lanza, M.D., will be delivering an opening Plenary Lecture at the '3rd International Conference on Cell Therapy', which will be held in Seoul, South Korea, on November 12, 2009. The Conference will focus on the gap between the bench and bedside, and will include sessions on 'Tissue Specific Stem Cell Therapy', 'Cancer Immune Cell Therapy', 'Cell Therapy for Diabetes' and 'Regenerative Medicine.' Dr. Lanza will be delivering a presentation titled "Embryonic and Induced Pluripotent Stem Cells - Moving from the Bench to the Bedside." During the presentation, Dr. Lanza is expected to discuss the company's various preclinical programs, including its retinal pigment epithelium (RPE) technology, which the Company plans to file an Investigation New Drug (IND) application this quarter to begin human clinical trials. After his presentation, Dr. Lanza will Chair the morning Plenary Session and Panel.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "esti
|SOURCE Advanced Cell Technology|
Copyright©2009 PR Newswire.
All rights reserved